Market Research Logo

Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)

Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)

‘Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which includes the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, family history and personal history are linked to the growth of breast cancer.

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, increasing adoption of minimally invasive procedures and rising awareness programs and research grants. However, growth of the market can be hindered by several factors including financial burden of breast cancer, drug development challenges in developing countries, long term side effects of drugs.

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the US, Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.


1. Introduction
1.1 Breast Cancer
1.2 Types
Table 1: Breast Cancer by Types
1.3 Stages
Table 2: Stages of Breast Cancer
Table 3: Stage Occurrence of Breast Cancer in Patients
1.4 Risk Factors
1.4 Symptoms & Diagnosis
1.5 Treatment
2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
Table 4: Global Breast Cancer Market by Value (2013-2017)
2.2 Global Breast Cancer Market Forecast by Value
Table 5: Global Breast Cancer Market Forecast by Value (2018-2022)
2.3 Global Breast Cancer Market by Region
Table 6: Global Breast Cancer Market by Region (2017)
2.4 Global Breast Cancer Drug Development by Stages
Table 7: Global Breast Cancer Drug Development by Stages (2017)
3. Regional Breast Cancer Market Analysis
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
Table 8: The U.S. Breast Cancer Market by Value (2013-2017)
3.1.2 The U.S. Breast Cancer Market Forecast by Value
Table 9: The U.S. Breast Cancer Market Forecast by Value (2018-2022)
3.1.3 The U.S. Breast Cancer Market by Addressable Population
Table 10: The U.S. Breast Cancer Market by Addressable Population (2013-2017)
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
Table 11: The U.S. Breast Cancer Market Forecast by Addressable Population (2018-2022)
3.1.5 The U.S. Breast Cancer Population by Age
Table 12: The U.S. Breast Cancer Population by Age & Type (2017)
3.1.6 The US HER2+ Node Positive Breast Cancer Patients Volume
Table 13: The US HER2+ Node Positive Breast Cancer Patients Volume (2017-2022)
3.1.7 The US HER2+ Node Negative Breast Cancer Patients Volume
Table 14: The US HER2+ Node Negative Breast Cancer Patients Volume (2017-2022)
3.1.8 The US HER2+ Node Negative (High Risk) Breast Cancer Patients Volume
Table 15: The US HER2+ Node Negative (High Risk) Breast Cancer Patients Volume (2017-2022)
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
Table 16: EU5 Breast Cancer Market by Value (2013-2017)
3.2.2 EU5 Breast Cancer Market Forecast by Value
Table 17: EU5 Breast Cancer Market Forecast by Value (2018-2022)
3.2.3 Europe HER2+ Node Positive Breast Cancer Patients Volume
Table 18: Europe HER2+ Node Positive Breast Cancer Patients Volume (2017-2022)
3.2.4 Europe HER2+ Node Negative Breast Cancer Patients Volume
Table 19: Europe HER2+ Node Negative Breast Cancer Patients Volume (2017-2022)
3.2.5 Europe HER2+ Node Negative (High Risk) Breast Cancer Patients Volume
Table 20: Europe HER+ Node Negative (High Risk) Breast Cancer Patients Volume (2017-2022)
3.3 APAC
3.3.1 APAC Breast Cancer Market by Value
Table 21: APAC Breast Cancer Market by Value (2013-2017)
3.3.2 APAC Breast Cancer Market Forecast by Value
Table 22: APAC Breast Cancer Market Forecast by Value (2018-2022)
3.3.3 APAC Breast Cancer Market by Countries
Table 23: APAC Breast Cancer Market by Countries (2017)
3.3.4 Japan’s Breast Cancer Market by Value
Table 24: Japan’s Breast Cancer Market by Value (2013-2017)
3.3.5 Japan’s Breast Cancer Market Forecast by Value
Table 25: Japan’s Breast Cancer Market Forecast by Value (2018-2022)
3.3.6 China’s Breast Cancer Market by Value
Table 26: China’s Breast Cancer Market by Value (2013-2017)
3.3.7 China’s Breast Cancer Market Forecast by Value
Table 27: China’s Breast Cancer Market Forecast by Value (2018-2022)
3.3.8 Australia’s Breast Cancer Market by Value
Table 28: Australia's Breast Cancer Market by Value (2013-2017)
3.3.9 Australia’s Breast Cancer Market Forecast by Value
Table 29: Australia's Breast Cancer Forecast Market by Value (2018-2022)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Consumption of Tobacco and Alcohol
Table 30: Global Cigarette Consumption (1990-2017)
4.1.2 Increasing Global Diabetic Population
Table 31: Global Diabetic Population (2013-2017)
4.1.3 Accelerating Obese Population
Table 32: Global Obese Population (2013-2017)
4.1.4 Increasing Healthcare Expenditure
Table 33: Global Healthcare Expenditure Per Capita (2013-2017)
4.1.5 Rising Female Population Aged 65 Years & Above
Table 34: Global Female Population Aged 65 Years and Above (2013-2017)
4.2 Key Trends & Developments
4.2.1 PARP Inhibitors under Development
Table 35: Key PARP Inhibitors Under Development (2017)
4.2.2 Rising Adoption of Minimally Invasive Procedures
4.2.3 Increasing Awareness Programs and Research Grants
4.3 Challenges
4.3.1 Financial Burden of Breast Cancer
4.3.2 Drug Development Challenges in Developing Countries
4.3.3 Long Term Side Effects
5. Competition
5.1 Global Market
5.1.1 Revenue Comparison by Company
Table 36: Revenue Comparison by Company (2017)
5.1.2 R&D Expenditure Comparison by Company
Table 37: R&D Expenditure Comparison by Company (2017)
5.1.3 Market Cap Comparison by Company
Table 38: Market Cap Comparison by Company (2017)
6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
Table 39: Johnson & Johnson Sales by Segments (2017)
6.1.2 Financial Overview
Table 40: Johnson & Johnson Sales and Net Earnings (2013-2017)
6.1.3 Business Strategies
Table 41: Johnson & Johnson Product Pipeline (2017)
6.2 AstraZeneca
6.2.1 Business Overview
Table 42: AstraZeneca Product Revenue by Region (2017)
6.2.2 Financial Overview
Table 43: AstraZeneca Revenue and Net Profit (2013-2017)
6.2.3 Business Strategies
Table 44: AstraZeneca Development Pipeline Overview (2017
6.3 AbbVie Inc.
6.3.1 Business Overview
Table 45: AbbVie Revenue by Product Segments (2017)
6.3.2 Financial Overview
Table 46: AbbVie Revenue and Net Earnings (2013-2017)
6.3.3 Business Strategies
Table 47: AbbVie Inc. Agreements (2017/2018)
Table 48: AbbVie Inc. Major Product Approvals (2017/2018)
6.4 Roche
6.4.1 Business Overview
Table 49: Roche Sales by Segments (2017)
6.4.2 Financial Overview
Table 50: Roche Sales and Net Income (2013-2017)
6.4.3 Business Strategies
Table 51: Roche Agreements (2017/2018)
Table 52: Roche Product Approvals & Launches (2017/2018)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report